PQ 912

Drug Profile

PQ 912

Alternative Names: PQ-912

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Probiodrug
  • Developer Covance; Probiodrug
  • Class Antidementias; Small molecules
  • Mechanism of Action Glutaminyl-peptide cyclotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Inflammation

Most Recent Events

  • 09 Jan 2017 Probiodrug completes enrolment in the SAPHIR phase IIa trial for Alzheimer's disease in Belgium, Finland, France, Germany, Netherlands, Sweden and Spain
  • 10 Nov 2016 Preclinical trials in Inflammation in Germany
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Switzerland (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top